摘要:
Processes for coating a carrier with microparticles of a drug are described. For example, a coated carrier can be obtained in a one-stage process that entails evaporating a solvent from microdroplets of a solution containing an API to obtain dry microparticles, which are then coated on the carrier.
摘要:
An apparatus is provided for the separation of a resin from a reaction mixture. The apparatus comprises a column fitted with a side port, two inlet/outlet ports, and two flanges. Each flange is fitted with a multilayer net screen supported by a support grid. The column itself is attached to a support structure. A process is provided for using this apparatus to remove a resin from a reaction mixture, wherein the reaction mixture is added to the apparatus and the resin is filtered off, remaining in the column as the waste leaves. The remaining resin is then washed and eluted to provide a purified product.
摘要:
This invention relates to an efficient process for converting gabapentin hydrochloride salt to gabapentin by liquid-liquid extraction using a counter-current extraction method.
摘要:
Levofloxacin was prepared by reacting (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid with N-methyl piperazine in a polar solvent or in a neat mixture to form levofloxacin. Further processing of the levofloxacin produced novel levofloxacin forms, including a hemihydrate and Forms A, B, C, F, G and H.
摘要:
The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same.
摘要:
A crystalline form of duloxetine hydrochloride, pharmaceutical compositions of the crystalline form of duloxetine hydrochloride, and methods of preparing the crystalline form of duloxetine hydrochloride are provided.
摘要:
The present invention describes processes for the preparation of O-desmethylvenlafaxine and the intermediates cyclohexylbenzylcyanide and tridesmethylvenlafaxine, which may be used as intermediates in preparing O- desmethylvenlafaxine.